Combination of EphrinB2 Inhibition and Pembrolizumab Use for Metastatic Urothelial Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma
J. Clin. Oncol 2022 Aug 19;[EPub Ahead of Print], S Sadeghi, D Quinn, T Dorff, S Pal, S Groshen, D Tsao-Wei, R Parikh, M Devitt, M Parikh, A Jackovich, N Ruel, N Vogelzang, E Burgess, I Siddiqi, IS Gill, PN Lara, R Dreicer, PS GillFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.